Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device

A biocompatible drug release matrix for a medical device comprising:

• a biocompatible drug eluting matrix comprising polybutylmethacrylate and polvethylenevinylacetate;
• and
• a drug incorporated into the biocompatible drug eluting matrix,
• wherein the drug is an analogue related to the quinone-containing alkylating agents of a mitomycin family and wherein the drug forms a plurality of small particles in a solution.

A biocompatible drug release matrix comprising:

• a biocompatible drug eluting matrix comprising a thermoplastic polyurethane elastomer;
• and
• a drug incorporated into the biocompatible drug eluting matrix,
• wherein the biocompatible drug eluting matrix is co-solubilized with the drug in a solvent to form a solution wherein the drug forms a plurality of small particles in the solution and the solvent is evaporated from the solution.

A biocompatible drug release matrix comprising:

• a biocompatible polymer matrix comprising polybutylmethacrylate and polvethylenevinylacetate;
• and
• a drug suspended within the biocompatible polymer matrix,
• wherein the drug is an analogue related to the quinone-containing alkylating agents of a mitomycin family and wherein the drug forms a plurality of small particles in a solution.

A biocompatible drug release matrix for a medical device comprising:

• a biocompatible drug eluting matrix comprising parylene and derivatives of parylene;
• and
• a drug incorporated into the biocompatible drug eluting matrix,
• wherein the biocompatible drug eluting matrix is co-solubilized with the drug in a solvent to form a solution wherein the drug forms a plurality of small particles in the solution and the solvent is evaporated from the solution to form a uniform distribution of drug in the biocompatible drug eluting matrix.

A biocompatible drug release matrix for a medical device comprising:

• a biocompatible polymer matrix comprising parylene and derivatives of parylene;
• and
• a drug suspended within the biocompatible polymer matrix,
• wherein the biocompatible polymer matrix is co-solubilized with the drug in a solvent to form a solution wherein the drug forms a plurality of small particles in the solution and the solvent is evaporated from the solution to form a uniform distribution of drug in the biocompatible polymer matrix.